Abstract. In vitro megakaryocyte differentiation is regulated by two activities: a megakaryocyte colony-stimulating activity (Mk-CSA), which is required for proliferation, and an auxiliary factor, megakaryocyte potentiating activity, which plays a role in later differentiation events. Tumor-promoting phorbol esters alter many cellular differentiation-related events. Thus, it was hypothesized that phorbol esters may bring about megakaryocyte differentiation in vitro. 4f3-Phorbol 12-myristate 13-acetate (PMA), when co-cultured with a source of Mk-CSA, stimulated a threefold increase in colony numbers. Co-culture of PMA and megakaryocyte potentiator activity did not stimulate colony formation, thus eliminating any action of PMA as an Mk-CSA. The direct effect of PMA on the formation of megakaryocyte colonies was established by (a) the function of PMA as a megakaryocyte potentiator in serum-free experiments, (b) the ability of PMA to stimulate megakaryocyte colony formation using bone marrow cells depleted of populations known to produce potentiating activity, (c) the inability of bone marrow adherent cells previously treated with phorbol, 12,13-dibutyrate (PDBu) to augment megakaryocyte colony formation, and (d) the ability of PMA to induce the growth of immature megakaryocytes into large single megakaryocytes. Structure:activity experiments resulted in equivalent activities for PMA and PDBu, whereas the nontumor promoter phorbol 12,13-diacetate and phorbol itself lacked activity.
Introduction
The development of megakaryocyte colonies from the murine megakaryocyte progenitor cells (colony-forming unit megakaryocytes, CFU-Mk)' requires the presence of two in vitro regulatory activities: (a) megakaryocyte colony-stimulating activity (Mk-CSA), an obligate factor for the proliferation of the progenitor cell in vitro (1-3), which is produced by a number of tissues, including a murine monomyelocytic leukemia adapted to suspension culture (WEHI-3) (4), and (b) megakaryocyte potentiator activity, produced by bone, bone marrow, spleen, and lung, which increases the DNA content of colonyderived murine megakaryocytes (5, 6) . Megakaryocyte potentiator activity also directly stimulates murine immature megakaryocytes to differentiate into single mature cells rather than colonies (7, 8) . This activity, which fails to affect cell proliferation, is necessary for full megakaryocyte development and stimulates an increase in size, and contents of cytoplasm and enzymes, of immature megakaryocytes (8) .
In other cell systems, such as the leukemic cell line HL60, or the pheochromocytoma cell line PC12, 4fl-phorbol 12-myristate 13-acetate (PMA) can induce cell differentiation (9, 10) . Given the proposed role of tumor-promoting phorbol derivatives in inducing terminal differentiation, it was hypothesized that phorbol esters may bring about megakaryocyte differentiation in vitro. In the following studies we show that PMA can bring about megakaryocyte differentiation and induce effects during megakaryocyte colony formation that are identical to those brought about by the biological sources of the differentiating factor, megakaryocyte potentiator activity. petri dishes were removed from the incubator, dried, and stained in situ for acetylcholinesterase activity (12) . Megakaryocyte colonies were counted at a magnification of 40. Serum-free experiments were carried out using McCoy's SA Medium (Gibco Laboratories) using conditions described by Iscove and Melchers (13) as previously modified by Long et al. (8) . Optimal levels of bovine serum albumin (BSA, 22 mg/ml), human transferrin (30 MAg/ml), both from Sigma Chemical Co., and lecithin (20 jig/ml; Associated Concen- trates, Woodside, Long Island, NY) were used in these bioassays. Serum-free WEHI-3 CM and mouse lung conditioned medium (MLuCM) were prepared as described (8) and used in these experiments.
Thus, these experiments were carried out in absolutely serum-free conditions.
In vitro assay for megakaryocyte maturation. Immature megakaryocytes were quantified as described elsewhere (14) . (7, 8) or by countercurrent centrifugal elutriation using an elutriator (model J-2 IM; Beckman Instruments, Inc., Fullerton, CA) (rotor speed 1,500 rpm, flow rate 6 ml/min, elution buffer was CATCH media [ 15] containing 1% BSA). Under these conditions, -3% of the total nucleated cells and 85-95% of the immature megakaryocytes remained in the elutriation chamber. These cells were then used as input cells for separation by a 1.5-h sedimentation velocity procedure. This method gave similar but faster separation of immature megakaryocytes than that reported (7, 8 Al of stimulatory factor, and 1 ml of serum-free McCoy's 5A Medium containing 0.3% agar (see above). The plates were incubated for 60 h, stained in situ for acetylcholinesterase (7, 8) , and examined at a magnification of 100 for the presence of single, mature megakaryocytes (7, 8 In a separate experiment, adherent cells (3 X 10' cell/ml) were coincubated with 10-6 M PMA for 3 d at 37°C and tested at 75-200 Ad/ ml for the ability to augment colony formation. No effect was seen with these CMs.
Separation by velocity sedimentation. Velocity sedimentation was performed at unit gravity according to the method of Miller and Phillips (17) . Bone marrow was obtained from 15-20 mice by flushing the femurs with cold (4°C) PBS. The cells were kept on ice during collection, and separation was carried out at 4°C. After sedimentation for 2.5 h, 35-ml fractions were collected and the cells harvested by centrifugation ( (Table II) . Conversely, bone marrow adherent cells were collected and stimulated with optimal concentrations of PDBu (10-6 M).
Feeder layers of these pretreated, washed, adherent cells failed to augment megakaryocyte colony formation (Table II) . This was true for all cell concentrations (3-12 X 10 cell/ml) tested. No differences were seen between PMA-and PBStreated adherent cells. The minimal number of colonies observed (Table II) Examination of the structure-activity relationship between various phorbol esters and megakaryocyte colony development. (Table III) . However, the EC50 (i.e., the concentration yielding 50% of maximal activity) for PMA and PDBu was 6.6 X 10-9 and 7.3 X 10-9 M, respectively, whereas the EC50 of mezerein was 8.3 X l0-8 M. At concentrations below 10-9 M, mezerein failed to augment megakaryocyte colony formation. Since mezerein inhibits phorbol binding in other cell systems (15) , we tested the ability of mezerein to block the functional effects of PMA or MLuCM on the murine megakaryocyte progenitor cell. Competition experiments indicated that mezerein (I0-'4-10-8 M) could inhibit the effect of 10-6 M PMA in a dose-related manner (Fig. 3) . Mezerein (10" M) also inhibited the actions of optimal levels of the biologically active MLuCM (Fig. 4) .
Effect of PMA on murine immature megakaryocytes. To establish further that PMA could induce megakaryocyte differentiation, we performed the following experiments. Murine immature megakaryocytes (i.e., megakaryocytes < 18 ,gm diam, having low amounts of acetylcholinesterase, and a high nucleus to cytoplasm ratio) respond to biologically active megakaryocyte potentiator activity in vitro by developing into single, mature megakaryocytes (7, 8) . We observed that PMA could substitute for the biologically active MLuCM in this assay (Table IV) . In the presence of PMA, murine immature megakaryocytes were induced to mature into single, large megakaryocytes. The immature megakaryocytes also responded similarly to the presence of TSF, another source of megakaryocyte potentiator activity (7, 8) .
Discussion
The tumor-promoting phorbol ester PMA can substitute for one of the in vitro stimulatory activities involved in the regulation of megakaryocytopoiesis-megakaryocyte potentiator activity. The effect of PMA on the formation of megakaryocyte colonies is shown by: the ability of PMA to function as a megakaryocyte potentiator in serum-free conditions; the inability of PMA-induced CMs and PDBu-treated, washed bone marrow adherent cell feeder layers to augment megakaryocyte colony formation; the ability of adherent-cell depleted bone marrow cells and cells sedimentating at 3-4 mm * h-' to respond to PMA; and the serum-free growth of immature megakaryocytes into mature megakaryocytes in the presence of PMA. PMA functions as a source of megakaryocyte potentiator activity when co-incubated with WEHI-3 CM (a source of Mk-CSA). The concentration of PMA used in these experiments is similar to that reported for the induction of differentiation in the HL60 cell line (9). PMA could not substitute for WEHI-3 CM in stimulating the proliferation of progenitor cells. When incubated with 10 bone marrow cells, neither PMA alone, nor the addition of MLuCM to PMA-containing cultures could stimulate colony formation. These observations indicate that PMA cannot function as a megakaryocyte colony-stimulating activity; i.e., it cannot bring about the proliferation and differentiation of progenitor cells into megakaryocytes even when co-cultured with optimal amounts of megakaryocyte potentiator activity (MLuCM). indicates that the accessory cells in the 5-6.5 mm * h-' fractions are not required for the PMA-induced augmentation of colony formation. Moreover, note that all of the megakaryocyte progenitor cell assays are routinely performed in the presence of prostaglandin E2, which inhibits the production of biological activities and macrophage colony formation (19, 11) . Finally, the pooled velocity sedimentation fractions (i.e., cells sedimenting from 8 to 16 mm h-') used in the megakaryocyte maturation assay are devoid of lymphocytes which sediment between 3-8 mm -h-' (17), thus eliminating lymphocyte subsets as a source of PMA-induced activities. Therefore, the effects of phorbol esters are not mediated by the population of auxiliary cells known to produce megakaryocyte potentiator activity (5, 8, 18) , nor do these effects seem to be mediated by lymphocytes. However, note that the target cell populations used in this study were relatively crude, being either unfractionated bone marrow or cells (immature megakaryocytes) enriched by velocity sedimentation. The use of CM rather than purified biological factors in most of these studies makes direct assessment of the role of Mk-CSA difficult. Given these limitations on the analyses performed, further characterization of the PMA response would be enhanced by using purified populations of stem cells, PMA, and purified Mk-CSA (the latter was used in portions of these studies).
The phorbol ester PMA also stimulates the in vitro maturation of immature megakaryocytes into large, single megakaryocytes. Murine immature megakaryocytes are small acetylcholinesterase-positive cells that are the progeny of the committed megakaryocyte progenitor (CFU-Mk), and have physical-chemical properties intermediate to those of the megakaryocyte progenitor cells and mature megakaryocytes (7, 8) . They differ from the progenitor cells in that they have lost their ability to proliferate (8) . The observation that such immature megakaryocytes respond to PMA substantiates the hypothesis that PMA is working on the megakaryocytic lineage.
Furthermore, it suggests that the responsiveness to phorbol esters extends from the progenitor cell through to at least the earliest morphologically recognizable megakaryocyte, the small acetylcholinesterase-positive cell. However, the 40% reduction in plating efficiency at 10' M implies that these cells may not be as sensitive to PMA as the progenitor cells.
Examination of the relationship between the structures of the phorbol esters and the ability of the CFU-Mk to respond to these agents indicates that these cells were stimulated by the tumor promotors PMA and PDBu. The non-tumorpromoting PDA and phorbol itself lacked this potentiating activity. Therefore, the ability of a phorbol ester to induce differentiation in the megakaryocytic lineage may be related to its in vivo actions as a tumor-promoting agent.
Mezerein affects the in vitro growth of megakaryocyte colonies in a biphasic manner. At high concentrations, mezerein has a limited ability to act as a megakaryocyte potentiator. This observation is consistent with mezerein's action as a weak tumor-promoting agent (20) . Low concentrations of mezerein can compete with, or inhibit, PMA-induced megakaryocyte colony growth in a dose-dependent manner. Such an observation is consistent with the ability of mezerein to specifically compete with PDBu in other systems (21) . Furthermore, mezerein at 10" M blocked the effects of biologically derived megakaryocyte potentiator activity MLuCM. This suggests that PMA and the biologically derived megakaryocyte potentiator activity either share a common receptor or share a final common mechanism for the induction of differentiation. Recently, a novel protein kinase (protein kinase C) has been characterized and is thought to play a role in mediating a variety of cellular membrane signals that fail to activate adenylate cyclase in their target tissues (22) . Protein kinase C has been shown to be calmodulin insensitive but requires phospholipid and calcium for activity (23) . Protein kinase C exists in very high levels in platelets (22) , and other observations suggest that protein kinase C may be the PMA receptor (24, 25) . Thus, protein kinase C may be the cellular site at which PMA and biologically derived megakaryocyte potentiator share common activities.
The observations presented in this study indicate that the phorbol ester PMA can bring about megakaryocyte differentiation and induce effects during megakaryocyte colony formation that are identical to those brought about by biological sources of megakaryocyte potentiator activity. The induction of megakaryocyte development by phorbol esters will allow systematic studies of the cellular mechanisms governing megakaryocyte differentiation. Also, if megakaryocyte differentiation is linked to protein kinase C activation, then these observations may elucidate general mechanisms of differentiation.
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